Crystalline form of olaparib and a process for preparing the same
AssigneeScinoPharm Taiwan, Ltd.
InventorsWen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang, Yung-Hung Chang, Kuan-Hsun Wang
Life of this patent
Estimating the term…
Abstract
In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe for preparing the novel crystalline form of olaparib. The process includes forming a solution comprising crude olaparib and an organic solvent; adding the solution to an anti-solvent to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form III of olaparib.
Claims17
Crystalline form III of olaparib, characterized by an X-ray powder diffraction pattern comprising peaks at 6.4, 6.8, 8.3 12.7, 15.0, 19.7, 22.0 and 23.0 degrees 2θ(±0.2 degrees 2θ);
- and further characterized by a differential scanning calorimetry thermogram, wherein the differential scanning calorimetry thermogram is substantially free of exothermic peaks between 50° C. to 250° C. in the heating process and comprises endothermic peaks at about 72.0, 144.6, and 212.5° C.
Dependencies are inferred from the claim text.